Healthcare DIVE July 16, 2025
States representing about 84% of Medicaid beneficiaries have signed onto an initiative that could broaden access to therapies like Vertex’s Casgevy and Bluebird’s Lyfgenia.
Nearly three dozen states have signed onto a U.S. government initiative designed to help improve access to gene therapies that can eliminate serious symptoms of sickle cell disease, but remain little-used because of their high price tags.
The CMS said on Wednesday that 33 states, plus the District of Columbia and Puerto Rico, will participate in the “Cell and Gene Therapy Access Model” to centrally coordinate insurance coverage for the treatments. Between 50% and 60% of people with sickle cell in the U.S. have Medicaid coverage and the participating states represent about 84% of Medicaid...
Today's Sponsors
Today's Sponsor